Article Details

Biopharma's New MASH Drug Has Two MOAs Research Report

Retrieved on: 2025-10-15 18:04:28

Tags for this article:

Click the tags to see associated articles and topics

Biopharma's New MASH Drug Has Two MOAs Research Report. View article details on hiswai:

Excerpt

Altimmune Inc.'s (ALT:NASDAQ) pemvidutide achieves metabolic improvement and directs hepatic anti-fibrotic activity with singular dosing, ...

Article found on: www.streetwisereports.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo